A Phase 2 Trial of JKN24011 in COPD

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary endpoint(s) modified Show 4 more changesShow less
    • Trial completed
    • Primary completion date changed from estimate of Apr 2026 to Apr 2, 2026
    • Study completion date changed from estimate of May 2026 to Apr 2, 2026
    • Eligibility criteria expanded, about 11 words
  2. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Efficacy and Safety of Subcutaneous JKN24011 in Patients With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD)
Trial Details
NCT Number NCT07440524
Lead Sponsor Joincare Pharmaceutical Group Industry Co., Ltd
Conditions
(from sponsor)		 COPD (Chronic Obstructive Pulmonary Disease)
Related terms Pulmonary Disease, Chronic Obstructive
Enrollment 215 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov